Gout and interleukins (IL) Archives - ACR Meeting Abstracts

Abstract Number: 2248 • ACR/ARHP Annual Meeting 2018
Genetic Variants Identify Interleukin 37 As an Important Anti-Inflammatory Cytokine in Gout in Humans
Viola Klück¹, Rosanne C. van Deuren¹, Amara Shaukat², Maartje Cleophas¹, Tania O. Crisan³, Nicola Dalbeth⁴, Lisa K. Stamp⁵, Tim Jansen⁶, Matthijs Janssen⁶, Alexander Hoischen¹, Frank van de Veerdonk⁷, Mihai Netea¹, Charles Dinarello⁸, Elan Z. Eisenmesser⁹, Vassili Kalabokis¹⁰, Soohyun Kim¹¹, Tony R. Merriman¹² and Leo .A.B. Joosten¹, ¹Experimental Internal Medicine, Radboud Institute of Molecular Life Sciences, Nijmegen, Netherlands, ²University of Otago, Dunedin, New Zealand, ³Medical Genetics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, ⁴Bone Rsch Grp/Dept of Med, University of Auckland, Auckland, New Zealand, ⁵Department of Medicine, University of Otago, Christchurch, New Zealand, ⁶VieCuri Medical Center, Venlo, Netherlands, ⁷Department of General Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ⁸Department of Medicine, Division of Infectious Diseases, University of Colorado, Denver, CO, ⁹Department of Biochemistry and Molecular Genetics, University of Colorado Denver, Aurora, CO, ¹⁰R&D Systems, BioTechne, Inc., Minneapolis, MN, ¹¹Laboratory of Cytokine Immunology, Konkuk University, Seoul, Korea, Republic of (South), ¹²Department of Biochemistry, School of Medical Sciences, University of Otago, Dunedin, New Zealand
Background/Purpose: During a gout flare monosodium urate (MSU) crystals induce, in the presence of a secondary stimulus, acute joint inflammation characterized by the recruitment of…
Abstract Number: 2344 • ACR/ARHP Annual Meeting 2015
A 3-Year Follow-up Study of Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant, or Unresponsive to Nonsteroidal Anti-Inflammatory Drugs and/or Colchicine
Naomi Schlesinger¹, Thomas Bardin^2,3, Mark Bloch⁴, Karine Lheritier⁵, Uwe Machein⁵, Guido Junge⁵, Alexander So⁶ and Rieke Alten⁷, ¹Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Hopital Lariboisière, Paris, France, ³Rhumatology Departement, Hôpital Lariboisière, Paris, France, ⁴Holdsworth House Medical Practice, Sydney, Australia, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶CHU Vaudois, University of Lausanne, Lausanne, Switzerland, ⁷Charité Univ Medicine, Berlin, Germany
Background/Purpose: Although anti-inflammatory drugs such as nonsteroidal anti-inflammatory drugs and colchicine are the recommended treatment options for pain and inflammation management in patients (pts) with…
Abstract Number: 2345 • ACR/ARHP Annual Meeting 2015
Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Long-Term Safety and Efficacy Results from a 36-Week Extension Study
Prashanth Sunkureddi¹, Rüdiger Moericke², Edith Tóth³, Jacques P Brown⁴, Uwe Machein⁵, Karine Lheritier⁵, Guido Junge⁵ and Alan J Kivitz⁶, ¹Clear Lake Rheumatology, Nassau Bay, TX, ²Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ³Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ⁴Centre Hospitalier de l'Université Laval (CHUL), Quebec City, QC, Canada, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Patients with gouty arthritis (GA) experience frequent flares with pain and inflammation. The limited available treatment options and typical comorbidities warrant effective alternative treatments1.…
Abstract Number: 174 • ACR/ARHP Annual Meeting 2014
Long Term Safety and Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results from a 36 Week Extension Study
P Sunkureddi¹, E Tóth², J. P Brown³, R Moericke⁴, D. Richard⁵, K Lheritier⁵, A Stancati⁵ and A Kivitz⁶, ¹Clear Lake Rheumatology, Nassau Bay, TX, ²Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ³CHU de Québec Research Centre and Laval University, Québec, QC, Canada, ⁴Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Gouty arthritis (GA) patients who experience frequent flares and have comorbidities have limited treatment options. Canakinumab (CAN), a selective, human, anti-interleukin1β monoclonal antibody, has…
Abstract Number: 175 • ACR/ARHP Annual Meeting 2014
Efficacy and Safety of Canakinumab in Acute Gouty Arthritis Patients with Chronic Kidney Disease Stage Greater Than or Equal to 3: A Post-Hoc Analysis of 12-Week Data
P Sunkureddi¹, E Tóth², J. P Brown³, A Kivitz⁴, A Stancati⁵, D. Richard⁵, K. Lheritier⁵ and R Moericke⁶, ¹Clear Lake Rheumatology, Nassau Bay, TX, ²Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ³CHU de Québec Research Centre and Laval University, Québec, QC, Canada, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany
Background/Purpose: Chronic kidney disease (CKD) limits the treatment options in acute gouty arthritis (GA) patients due to intolerance and contraindications to available therapies. Efficacy and…
Abstract Number: 1177 • ACR/ARHP Annual Meeting 2013
Efficacy and Safety Of Canakinumab Pre-Filled Syringe Versus Triamcinolone Acetonide In Acute Gouty Arthritis Patients
Prashanth Sunkureddi¹, Edith Toth², Jacques P. Brown³, Rüdiger Möricke⁴, Jan Michael Nebesky⁵, Gerhard Krammer⁵, Aiyang Tao⁶, Markus John⁵ and Alan Kivitz⁷, ¹Rheumatology, Clear Lake Rheumatology, Nassau Bay, TX, ²Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ³CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ⁴Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Canakinumab (CAN), a selective, fully human, monoclonal anti-IL-1β antibody has demonstrated long-term benefits in gouty arthritis (GA) patients (pts) by targeting the inflammatory pathway…

Abstracts tagged "Gout and interleukins (IL)"

Genetic Variants Identify Interleukin 37 As an Important Anti-Inflammatory Cytokine in Gout in Humans

A 3-Year Follow-up Study of Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant, or Unresponsive to Nonsteroidal Anti-Inflammatory Drugs and/or Colchicine

Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Long-Term Safety and Efficacy Results from a 36-Week Extension Study

Long Term Safety and Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results from a 36 Week Extension Study

Efficacy and Safety of Canakinumab in Acute Gouty Arthritis Patients with Chronic Kidney Disease Stage Greater Than or Equal to 3: A Post-Hoc Analysis of 12-Week Data

Efficacy and Safety Of Canakinumab Pre-Filled Syringe Versus Triamcinolone Acetonide In Acute Gouty Arthritis Patients